论文部分内容阅读
目前临床上关于内镜甲状腺癌根治术争议的焦点是原发肿瘤和颈淋巴结的安全切除范围。虽然缺乏相关的临床长期随访资料的支持,但现有的临床对照研究和短期随访结果已初步证明,将内镜甲状腺癌根治术应用于部分选择性病例的外科治疗,在技术上是安全、可行的。鉴于各种径路内镜甲状腺手术操作特点的差异,经胸乳径路内镜手术的适应证仅限于甲状腺乳头状微小癌,而经胸骨上窝小切口内镜辅助甲状腺手术的应用范围已拓展到部分低危乳头状癌病人。
At present, the focus of clinical controversy on endoscopic thyroidectomy is the safe resection range of primary tumors and cervical lymph nodes. Although there is a lack of support for relevant clinical long-term follow-up data, the current clinical controlled studies and short-term follow-up results have initially demonstrated that the use of endoscopic thyroidectomy for the surgical treatment of partially-selected cases is technically safe and feasible of. In view of the differences in pathological characteristics of endoscopic thyroidectomy, the indications of endoscopic thymectomy are limited to thyroid papillary microcarcinoma, and the scope of application of endoscopic assisted thyroidectomy through the suprasternal superior incision has been extended to some Low-risk papillary carcinoma patients.